Citation: Yan SU, Meng-Meng WANG, Hong-Ke LIU, Zhi SU. Synthesis and Antitumor Properties of Temozolomide-Based Platinum(Ⅳ) Complexes[J]. Chinese Journal of Inorganic Chemistry, ;2022, 38(3): 430-440. doi: 10.11862/CJIC.2022.044 shu

Synthesis and Antitumor Properties of Temozolomide-Based Platinum(Ⅳ) Complexes

School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China

Corresponding author: Hong-Ke LIU, liuhongke@njnu.edu.cn Zhi SU, zhisu@njnu.edu.cn
Received Date: 9 September 2021
Revised Date: 14 December 2021

Figures(9)

Temozolomide is the first-line anticancer drug for the clinical treatment of glioblastoma. In this work, temozolomide was chemically modified and introduced into the platinum(Ⅳ) complex. Two new Pt(Ⅳ) complexes P1T and P2T were successfully synthesized and characterized by ¹H NMR and ¹³C NMR. The results show that both complexes had good lipid solubility with a fast hydrolysis rate. The anticancer activity and the mechanism of P1T and P2T were investigated with the MTT assay, flow cytometry, confocal imaging, and western blot. The results demonstrate that complexes P1T and P2T owned high cytotoxicity to glioma cell line A261, but low toxicity to normal nerve cell HT-22, indicating good cancer cell selectivity. Flow cytometry reveals that complexes P1T and P2T arrest the cell cycle in the G2/M phase, leading to DNA damage and ultimately inducing tumor cell apoptosis.
- temozolomide,
- platinum complex,
- glioblastoma,
- anticancer drug
1. [1]
  Louis D N, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee W K, Ohgaki H, Wiestler O D, Kleihues P, Ellison D W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary[J]. Acta Neuropathol., 2016,131(6):803-820. doi: 10.1007/s00401-016-1545-1
2. [2]
  Giese A, Bjerkvig R, Berens M E, Westphal M. Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment[J]. J. Clin. Oncol., 2003,21(8):1624-1636. doi: 10.1200/JCO.2003.05.063
3. [3]
  Affronti M L, Heery C R, Herndon J E, Rich J N, Reardon D A, Desjardins A, Vredenburgh J J, Friedman A H, Bigner D D, Friedman H S. Overall Survival of Newly Diagnosed Glioblastoma Patients Receiving Carmustine Wafers Followed by Radiation and Concurrent Temozolomide plus Rotational Multiagent Chemotherapy[J]. Cancer, 2009,115(15):3501-3511. doi: 10.1002/cncr.24398
4. [4]
  de Souza R M, Shaweis H, Han C, Sivasubramaniam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, Hurwitz V, Bhangoo R, Gullan R, Ashkan K. Erratum: Has the Survival of Patients with Glioblastoma Changed over the Years?[J]. Br. J. Cancer, 2016,114(2):146-150. doi: 10.1038/bjc.2015.421
5. [5]
  Stupp R, Taillibert S, Kanner A, Read W, Steinberg D M, Lhermitte B, Toms S, Idbaih A, Ahluwalia M S, Fink K, Di Meco F, Lieberman F, Zhu J J, Stragliotto G, Tran D D, Brem S, Hottinger A F, Kirson E D, Lavy-Shahaf G, Weinberg U, Kim C Y, Paek S H, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi M E, Ram Z. Effect of Tumor-Treating Fields plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial[J]. JAMA - J. Am. Med. Assoc., 2017,318(23):2306-2316. doi: 10.1001/jama.2017.18718
6. [6]
  Furnari F B, Fenton T, Bachoo R M, Mukasa A, Stommel J M, Stegh A, Hahn W C, Ligon K L, Louis D N, Brennan C, Chin L, DePinho R A, Cavenee W K. Malignant Astrocytic Glioma: Genetics, Biology, and Paths to Treatment[J]. Genes Dev., 2007,21(21):2683-2710. doi: 10.1101/gad.1596707
7. [7]
  Fan C H, Liu W L, Cao H, Wen C, Chen L, Jiang G. O⁶-Methylgua-nine DNA Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant Gliomas[J]. Cell Death Dis., 2013,4(10)e876. doi: 10.1038/cddis.2013.388
8. [8]
  Hirose Y, Berger M S, Pieper R O. p53 Effects both the Duration of G₂ & M Arrest and the Fate of Temozolomide-Treated Human Glioblas- toma Cells[J]. Cancer Res., 2001,61(5):1957-1963.
9. [9]
  Friedman H S, Kerby T, Calvert H. Temozolomide and Treatment of Malignant Glioma[J]. Clin. Cancer Res., 2000,6(7):2585-2597.
10. [10]
  Gerson S L. MGMT: Its Role in Cancer Aetiology and Cancer Thera-peutics[J]. Nat. Rev. Cancer, 2004,4(4):296-307. doi: 10.1038/nrc1319
11. [11]
  Lee S Y. Temozolomide Resistance in Glioblastoma Multiforme[J]. Genes Dis., 2016,3(3):198-210. doi: 10.1016/j.gendis.2016.04.007
12. [12]
  Stupp R, Mason W P, van den Bent M J, Weller M, Fisher B, Taphoorn M J B, Belanger K, Brandes A A, Marosi C, Bogdahn U, Curschmann J, Janzer R C, Ludwin S K, Gorlia T, Allgeier A, Lacombe D, Cairncross J G, Eisenhauer E, Mirimanoff R O. Radio-therapy plus Concomitant and Adjuvant Temozolomide for Glioblas-toma[J]. N. Engl. J. Med., 2005,352(10):987-996. doi: 10.1056/NEJMoa043330
13. [13]
  Stupp R, Hegi M E, Mason W P, Bent M J, Taphoorn M J B, Janzer R C, Ludwin S K, Allgeier A, Fisher B, Belanger K, Hau P, Brandes A A, Gijtenbeek J, Marosi C, Vecht C J, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross J G, Mirimanoff R O. Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase Ⅲ Study: 5-Year Analysis of the EORTC-NCIC Trial[J]. Lancet Oncol., 2009,10(5):459-466. doi: 10.1016/S1470-2045(09)70025-7
14. [14]
  Rosenberg B, Vancamp L, Trosko J E, Mansour V H. Platinum Com- pounds: A New Class of Potent Antitumour Agents[J]. Nature, 1969,222(5191):385-386. doi: 10.1038/222385a0
15. [15]
  Wang X H, Wang X Y, Jin S X, Muhammad N, Guo Z J. Stimuli-Responsive Therapeutic Metallodrugs[J]. Chem. Rev., 2019,119(2):1138-1192. doi: 10.1021/acs.chemrev.8b00209
16. [16]
  JIN S X, GUO Z J, WANG X Y. Antitumor Metal Complexes Target-ing Energy Metabolism[J]. Progress in Pharmaceutical Sciences, 2020,44(4):280-293.
17. [17]
  Klein A V, Hambley T W. Platinum Drug Distribution in Cancer Cells and Tumors[J]. Chem. Rev., 2009,109(10):4911-4920. doi: 10.1021/cr9001066
18. [18]
  Dilruba S, Kalayda G V. Platinum-Based Drugs: Past, Present and Future[J]. Cancer Chemother. Pharmacol., 2016,77(6):1103-1124. doi: 10.1007/s00280-016-2976-z
19. [19]
  Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular Mechanisms of Cisplatin Resis-tance[J]. Oncogene, 2012,31(15):1869-1883. doi: 10.1038/onc.2011.384
20. [20]
  Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bel-lan A, Castedo M, Kroemer G. Systems Biology of Cisplatin Resis-tance: Past, Present and Future[J]. Cell Death Dis., 2014,5(5)e1257. doi: 10.1038/cddis.2013.428
21. [21]
  Wang X Y, Guo Z J. Targeting and Delivery of Platinum-Based Anti-cancer Drugs[J]. Chem. Soc. Rev., 2013,42(1):202-224. doi: 10.1039/C2CS35259A
22. [22]
  Oun R, Moussa Y E, Wheate N J. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists[J]. Dalton Trans., 2018,47(19):6645-6653. doi: 10.1039/C8DT00838H
23. [23]
  Karasawa T, Steyger P S. An Integrated View of Cisplatin-Induced Nephrotoxicity and Ototoxicity[J]. Toxicol. Lett., 2015,237(3):219-227. doi: 10.1016/j.toxlet.2015.06.012
24. [24]
  Johnstone T C, Suntharalingam K, Lippard S J. The Next Generation of Platinum Drugs: Targeted Pt Agents, Nanoparticle Delivery, and Pt Prodrugs[J]. Chem. Rev., 2016,116(5):3436-3486. doi: 10.1021/acs.chemrev.5b00597
25. [25]
  Wilson J J, Lippard S J. Synthetic Methods for the Preparation of Platinum Anticancer Complexes[J]. Chem. Rev., 2014,114(8):4470-4495. doi: 10.1021/cr4004314
26. [26]
  Hall M D, Hambley T W. Platinum Antitumour Compounds: Their Bioinorganic Chemistry[J]. Coord. Chem. Rev., 2002,232(1):49-67.
27. [27]
  Jin S X, Hao Y Y, Zhu Z Z, Muhammad N, Zhang Z Q, Wang K, Guo Y, Guo Z J, Wang X Y. Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum Complexes[J]. Inorg. Chem., 2018,57(17):11135-11145. doi: 10.1021/acs.inorgchem.8b01707
28. [28]
  Shi Y, Liu S A, Kerwood D J, Goodisman J, Dabrowiak J C. Pt Complexes as Prodrugs for Cisplatin[J]. J. Inorg. Biochem., 2012,107(1):6-14. doi: 10.1016/j.jinorgbio.2011.10.012
29. [29]
  Arrowsmith J, Jennings S A, Clark A S, Stevens M F G. Antitumor Imidazotetrazines. 41. Conjugation of the Antitumor Agents Mitozolo-mide and Temozolomide to Peptides and Lexitropsins Bearing DNA Major and Minor Groove-Binding Structural Motifs[J]. J. Med. Chem., 2002,45(25):5458-5470.
30. [30]
  Huang H Y, Yu B L, Zhang P Y, Huang J J, Chen Y, Gasser G, Ji L N, Chao H. Highly Charged Ruthenium Polypyridyl Complexes as Lysosome-Localized Photosensitizers for Two-Photon Photodynamic Therapy[J]. Angew. Chem. Int. Ed., 2015,54(47):14049-14052. doi: 10.1002/anie.201507800
31. [31]
  Huang H Y, Zhang P Y, Yu B L, Chen Y, Wang J Q, Ji L N, Chao H. Targeting Nucleus DNA with a Cyclometalated Dipyridophenazineru-thenium Complex[J]. J. Med. Chem., 2014,57(21):8971-8983. doi: 10.1021/jm501095r
32. [32]
  Oldfield S P, Hall M D, Platts J A. Calculation of Lipophilicity of a Large, Diverse Dataset of Anticancer Platinum Complexes and the Relation to Cellular Uptake[J]. J. Med. Chem., 2007,50(21):5227-5237. doi: 10.1021/jm0708275
33. [33]
  Bonner W M, Redon C E, Dickey J S, Nakamura A J, Sedelnikova O A, Solier S, Pommier Y. γH2AX and Cancer[J]. Nat. Rev. Cancer, 2008,8(12):957-967. doi: 10.1038/nrc2523
34. [34]
  Revet I, Feeney L, Bruguera S, Wilson W, Dong T K, Oh D H, Dankort D, Cleaver J E. Functional Relevance of the Histone γH2Ax in the Response to DNA Damaging Agents[J]. Proc. Natl. Acad. Sci. U. S. A., 2011,108(21):8663-8667. doi: 10.1073/pnas.1105866108
35. [35]
  Shieh S Y, Ikeda M, Taya Y, Prives C. DNA Damage-Induced Phos-phorylation of p53 Alleviates Inhibition by MDM2[J]. Cell, 1997,91(3):325-334. doi: 10.1016/S0092-8674(00)80416-X
36. [36]
  Wang D, Lippard S J. Cellular Processing of Platinum Anticancer Drugs[J]. Nat. Rev. Drug Discovery, 2005,4(4):307-320. doi: 10.1038/nrd1691
37. [37]
  Zhou Z J, Song J B, Nie L M, Chen X Y. Reactive Oxygen Species Generating Systems Meeting Challenges of Photodynamic Cancer Therapy[J]. Chem. Soc. Rev., 2016,45(23):6597-6626. doi: 10.1039/C6CS00271D
38. [38]
  WU J, TAO Q, GE C, XUE X L, QIAN Y, LIU H K. Synthesis and Antitumor Properties of Ruthenium-Arene Complexes Based on Nat-ural Product Perillol[J]. Chinese J. Inorg. Chem., 2020,36(7):1223-1232.
39. [39]
  Wang F X, Liang J H, Zhang H, Wang Z H, Wan Q, Tan C P, Ji L N, Mao Z W. Mitochondria-Accumulating Rhenium Tricarbonyl Com-plexes Induce Cell Death via Irreversible Oxidative Stress and Gluta-thione Metabolism Disturbance[J]. ACS Appl. Mater. Interfaces, 2019,11(14):13123-13133. doi: 10.1021/acsami.9b01057
40. [40]
  Carneiro B A, El-Deiry W S. Targeting Apoptosis in Cancer Therapy[J]. Nat. Rev. Clin. Oncol., 2020,17(7):395-417. doi: 10.1038/s41571-020-0341-y
1. [1]
  Chunmei GUO , Weihan YIN , Jingyi SHI , Jianhang ZHAO , Ying CHEN , Quli FAN . Facile construction and peroxidase-like activity of single-atom platinum nanozyme. Chinese Journal of Inorganic Chemistry, 2024, 40(9): 1633-1639. doi: 10.11862/CJIC.20240162
2. [2]
  Qilu DU , Li ZHAO , Peng NIE , Bo XU . Synthesis and characterization of osmium-germyl complexes stabilized by triphenyl ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(6): 1088-1094. doi: 10.11862/CJIC.20240006
3. [3]
  Haitang WANG , Yanni LING , Xiaqing MA , Yuxin CHEN , Rui ZHANG , Keyi WANG , Ying ZHANG , Wenmin WANG . Construction, crystal structures, and biological activities of two Ln^Ⅲ₃ complexes. Chinese Journal of Inorganic Chemistry, 2024, 40(8): 1474-1482. doi: 10.11862/CJIC.20240188
4. [4]
  Jingjing QING , Fan HE , Zhihui LIU , Shuaipeng HOU , Ya LIU , Yifan JIANG , Mengting TAN , Lifang HE , Fuxing ZHANG , Xiaoming ZHU . Synthesis, structure, and anticancer activity of two complexes of dimethylglyoxime organotin. Chinese Journal of Inorganic Chemistry, 2024, 40(7): 1301-1308. doi: 10.11862/CJIC.20240003
5. [5]
  Xin MA , Ya SUN , Na SUN , Qian KANG , Jiajia ZHANG , Ruitao ZHU , Xiaoli GAO . A Tb₂ complex based on polydentate Schiff base: Crystal structure, fluorescence properties, and biological activity. Chinese Journal of Inorganic Chemistry, 2024, 40(7): 1347-1356. doi: 10.11862/CJIC.20230357
6. [6]
  Yingchun ZHANG , Yiwei SHI , Ruijie YANG , Xin WANG , Zhiguo SONG , Min WANG . Dual ligands manganese complexes based on benzene sulfonic acid and 2, 2′-bipyridine: Structure and catalytic properties and mechanism in Mannich reaction. Chinese Journal of Inorganic Chemistry, 2024, 40(8): 1501-1510. doi: 10.11862/CJIC.20240078
7. [7]
  Zhaoyang WANG , Chun YANG , Yaoyao Song , Na HAN , Xiaomeng LIU , Qinglun WANG . Lanthanide(Ⅲ) complexes derived from 4′-(2-pyridyl)-2, 2′∶6′, 2″-terpyridine: Crystal structures, fluorescent and magnetic properties. Chinese Journal of Inorganic Chemistry, 2024, 40(8): 1442-1451. doi: 10.11862/CJIC.20240114
8. [8]
  Xinting XIONG , Zhiqiang XIONG , Panlei XIAO , Xuliang NIE , Xiuying SONG , Xiuguang YI . Synthesis, crystal structures, Hirshfeld surface analysis, and antifungal activity of two complexes Na(Ⅰ)/Cd(Ⅱ) assembled by 5-bromo-2-hydroxybenzoic acid ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(9): 1661-1670. doi: 10.11862/CJIC.20240145
9. [9]
  Yuanpei ZHANG , Jiahong WANG , Jinming HUANG , Zhi HU . Preparation of magnetic mesoporous carbon loaded nano zero-valent iron for removal of Cr(Ⅲ) organic complexes from high-salt wastewater. Chinese Journal of Inorganic Chemistry, 2024, 40(9): 1731-1742. doi: 10.11862/CJIC.20240077
10. [10]
  Yujia LI , Tianyu WANG , Fuxue WANG , Chongchen WANG . Direct Z-scheme MIL-100(Fe)/BiOBr heterojunctions: Construction and photo-Fenton degradation for sulfamethoxazole. Chinese Journal of Inorganic Chemistry, 2024, 40(3): 481-495. doi: 10.11862/CJIC.20230314
11. [11]
  Zongfei YANG , Xiaosen ZHAO , Jing LI , Wenchang ZHUANG . Research advances in heteropolyoxoniobates. Chinese Journal of Inorganic Chemistry, 2024, 40(3): 465-480. doi: 10.11862/CJIC.20230306
12. [12]
  Chuanming GUO , Kaiyang ZHANG , Yun WU , Rui YAO , Qiang ZHAO , Jinping LI , Guang LIU . Performance of MnO₂-0.39IrO_x composite oxides for water oxidation reaction in acidic media. Chinese Journal of Inorganic Chemistry, 2024, 40(6): 1135-1142. doi: 10.11862/CJIC.20230459
13. [13]
  Endong YANG , Haoze TIAN , Ke ZHANG , Yongbing LOU . Efficient oxygen evolution reaction of CuCo₂O₄/NiFe-layered bimetallic hydroxide core-shell nanoflower sphere arrays. Chinese Journal of Inorganic Chemistry, 2024, 40(5): 930-940. doi: 10.11862/CJIC.20230369
14. [14]
  Qiangqiang SUN , Pengcheng ZHAO , Ruoyu WU , Baoyue CAO . Multistage microporous bifunctional catalyst constructed by P-doped nickel-based sulfide ultra-thin nanosheets for energy-efficient hydrogen production from water electrolysis. Chinese Journal of Inorganic Chemistry, 2024, 40(6): 1151-1161. doi: 10.11862/CJIC.20230454
15. [15]
  Yan LIU , Jiaxin GUO , Song YANG , Shixian XU , Yanyan YANG , Zhongliang YU , Xiaogang HAO . Exclusionary recovery of phosphate anions with low concentration from wastewater using a CoNi-layered double hydroxide/graphene electronically controlled separation film. Chinese Journal of Inorganic Chemistry, 2024, 40(9): 1775-1783. doi: 10.11862/CJIC.20240043

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(748)
HTML views(143)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142